Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2018.8532

OL-0-0-8532

Articles

Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients

Liangliang

1 * Liu

Hongyu

2 * Guo

Hongchuan

3 * Wu

Qiong

4 Yu

Songyan

5 Qin

Yuanyuan

6 Wang

Gang

1 Wu

Qiyan

1 Zhang

Rong

7 Wang

Lingxiong

1 Zhang

Lijun

1 Liu

Chunxi

1 Jiao

Shunchang

1 Liu

Tianyi

1Department of Oncology, Chinese PLA General Hospital, Beijing 100853, P.R. China 2Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, P.R. China 3Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China 4Department of Gynaecology and Obstetrics, Dongzhimen Hospital, Beijing 100700, P.R. China 5Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, P.R. China 6Department of Blood Transfusion, Chinese PLA General Hospital, Beijing 100853, P.R. China 7Department of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba 277-8577, Japan

Correspondence to: Professor Tianyi Liu or Professor Shunchang Jiao, Department of Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, P.R. China, E-mail: tianyiliu08@hotmail.com, E-mail: jiaosc@vip.sina.com *

Contributed equally

06 2018

18 04 2018

15 6 9507 9515 17092017 20032018

2018

Myeloid-derived suppressor cells (MDSCs) serve an immunosuppressive role in human tumors. Human Lin^−/low human leukocyte antigen-antigen D related (HLA-DR⁻) cluster of differentiation (CD)-11b⁺CD33⁺ MDSCs are closely linked with tumor staging, progression, clinical therapeutic efficacy and prognosis for various types of tumors. The present study employed multiparametric flow cytometry to measure the proportion of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs in the peripheral blood of 105 cervical cancer patients and 50 healthy subjects. The level of MDSC was higher in tumor patients than in the normal control group and this was closely associated with clinical staging. Further analysis of tumor-infiltrating MDSCs was performed in 22 patients. The MDSC proportions in tumor tissue were significantly higher than those in the corresponding adjacent tissue. The phenotypic characteristics of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs were then evaluated and the results revealed that they express high CD13 and CD39, and low CD115, CD117, CD124 and programmed cell death ligand 1; they were also devoid of CD14, CD15 and CD66b. MDSCs and T-cells from peripheral blood were sorted by flow cytometry for co-culture experiments. Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs from patients significantly inhibited the proliferation of CD4 and CD8 T-cells. Furthermore, functional analysis verified that MDSCs from cervical cancer patients could inhibit interleukin-2 and interferon-γ production from T-cells. In addition, the associations between peripheral circulating MDSCs and tumor infiltrating MDSCs, and tumor relapse and metastasis were analyzed. The number of peripheral MDSCs and MDSCs in tumor tissue were observed to be associated with relapse-free survival. Thus, MDSCs in the peripheral blood and tumors of cervical cancer patients have a significant immunosuppressive effect, and are associated with cervical cancer staging and metastasis. These results suggest that targeting MDSCs may increase antitumor immunity and increase the efficacy of cervical cancer therapies.

cervical cancer immunosuppressive myeloid-derived suppressor cells T cells

Introduction

Cervical cancer, a malignant tumor, is the fourth most common cancer in women. The main cause of cervical cancer is continuous infection with human papilloma virus (HPV) (1–4). Cervical cancer cells rapidly evade the immune system and promote tumor progression by inhibiting antitumor immunity (5–8). Many reports have demonstrated the expansion of various immunosuppressive cells such as regulatory T cells, tumor-associated macrophages, myeloid-derived suppressor cells (MDSCs), and N2 neutrophils in cervical tumors (7–10). Therefore, understanding changes in immunosuppressive cells is important for tumor diagnosis and treatment.

In cancer patients and animal tumor models, there is a significant accumulation of MDSCs, a heterogeneous and diverse population, in the blood, lymph nodes, bone marrow, and cancer tissues, and they can inhibit innate and adaptive immune responses (11,12); this represents an important mechanism of immune evasion for tumor cells. MDSCs have different phenotypes, based on factors secreted during bone marrow differentiation and by tumor cells, which affect cell differentiation (13). In mice, CD11b and Gr-1 are used as specific markers of MDSCs. Further studies divided mouse MDSCs into two major subsets, namely monocytic (Gr-1⁺Ly6C⁺) and granulocytic (Gr-1⁺Ly6G⁺) (14). In contrast, human MDSCs are not associated with widely recognized specific markers (15,16). However, similarly, they can also be classified as granulocytic (CD15, CD66b, and CD33-expressing) and monocytic (CD14-expressing). In kidney cancer patients, CD14⁻CD15⁺CD11b⁺CD66⁺ granulocytic MDSCs are immunosuppressive (17). Various MDSC phenotypes in non-small cell lung cancer include Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺, Lin^−/lowHLA-DR⁻CD33⁺, CD14⁺S100A9⁺, CD14⁻CD15⁺CD11b⁺CD33⁺, and CD14⁺HLA-DR⁻ have been confirmed (18–22). In addition, the immunosuppressive effects of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs have been reported in human malignant gliomas, breast cancers, colon cancers, and kidney cancers (13,23–25), and increased MDSC levels are associated with tumor burden and prognosis in breast and colon cancer patients (19).

In the current study, the level of MDSCs in the peripheral blood of 105 patients with different clinical stages and in tumor tissue and corresponding adjacent tissue of 22 clinical specimens were assessed. Cellular subsets and phenotypic characteristics and function of these cells were analyzed. The accumulated evidence can contribute to understanding the clinical characteristics of peripheral blood and local tumor-infiltrating Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs in cervical cancer.

Materials and methods <sec> <title>Ethics statement

All cervical carcinoma patients and healthy donors provided written informed consent prior to blood sampling and/or tumor tissue harvesting. The research protocol was approved by the Medical Ethics Committee of Chinese PLA General Hospital (Beijing, China) and the 307th Hospital of Chinese PLA (Beijing, China).

Patients

Control samples from healthy volunteers (n=50) and cervical cancer patient samples (n=105) were obtained at the gynecology departments of the Chinese PLA general hospital and the 307th Hospital of Chinese PLA. All patients were newly diagnosed and treatment-naive. Table I shows the clinical characteristics of patients included in this study.

Flow cytometry

Blood samples for the detection of peripheral circulating MDSCs were collected using EDTA anticoagulant tubes (BD Biosciences, Franklin Lakes, NJ, USA). Monoclonal fluorescent antibodies, CD11b-PECY7 (cat. no. A54822), HLA-DR-ECD (cat. no. IM3636), and CD33-PECY5 (cat. no. IM26 47 U), were from Beckman Coulter, Inc., (Brea, CA, USA). Lineage (CD3, CD14, CD16, CD19, CD20, and CD56-FITC) (cat. no. 340546) antibodies were all from BD Biosciences. Four-color analysis was used to confirm MDSCs. Analysis of tumor-infiltrating MDSCs was performed using anti-human CD45-FITC (cat. no. 304006), CD11b-PECY7 (cat. no. A54822), and CD33-PECY5 (cat. no. IM2647 U; all from BioLegend, Inc., San Diego, CA, USA). For phenotypic characterization of MDSCs, the MDSC population was gated for the analysis of PE expression. Antibodies involved in phenotype analysis included CD13-PE (cat. no. 301703), CD39-PE (cat. no. 328208), CD34-PE (cat. no. 343505), CD73-PE (cat. no. 344004), CD66b-PE (cat. no. 305105), CD115 (CSF-1R)-PE (cat. no. 347303), PD-1 (CD279)-PE (cat. no. 329906), CD124 (IL-4Ra)-PE (cat. no. 355003), PD-L1 (CD274)-PE (cat. no. 329706), and PD-L2 (CD273)-PE (cat. no. 329606). Isotype control antibodies (Mouse IgG1-PE, cat. no. 400114; Mouse IgM-PE, cat. no. 401611; Mouse IgG2a-PE, cat. no. 400214; Mouse IgG2b-PE, cat. no. 401208; Rat IgG1-PE, cat. no. 400408) were used as controls. Beforementioned antibodies were from BioLegend, Inc. For the detection of peripheral blood and tumor-infiltrating cell phenotypes, a standard amount of corresponding antibody was added. Subsequently, 500 µl of OptiLyse C Lysing Solution (cat. no. A11895; Beckman Coulter, Inc.) was added to each blood sample and incubated for 15 min; 500 µl PBS was then added before 500 µl of FACS buffer was added; analysis was performed by flow cytometry. For intracellular cytokine staining, purified MDSCs were added at a ratio of 1:1 to the control group (lymphocytes alone) or to the experimental group. Cell Stimulation cocktail plus protein transport inhibitors (eBioscience; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was added to each group for 4 h of stimulation. Cell surface marker staining was performed using CD3-ECD (cat. no. A07748), CD4-PC5 (cat. no. IM2636 U), and CD8-PECY7 (cat. no. 6607102) (all from Beckman Coulter, Inc.). The BD Cytofix/Cytoperm™ Plus Fixation/Permeabilization kit (cat. no. 555028) reagent box was used to process cells before intracellular cytokine staining using IL-2-PE (cat. no. 506709) and IFNg-FITC (cat. no. 552887) antibodies and corresponding isotype control antibodies (Rat IgG2a-PE, cat. no. 559317; Mouse IgG1-FITC, cat. no. 556649; all from BD Biosciences). After treatment, cells were analyzed by flow cytometry for the production of T-cell cytokines. Samples were obtained using a flow cytometer FC500-MPL (Beckmam Coulter, Inc.), and data analysis was performed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). Absolute MDSC counts were calculated using the following formula: [total white blood cell count (cells/ml) percent MDSCs]/100 or [total tumor-infiltrating immune cell count (cells/100 mg tumor) percent MDSCs]/100.

Cell separation

Separation of PBMCs was performed using density gradient centrifugation. Briefly, blood samples with EDTA anticoagulant were carefully separated by Ficoll-Hypaque (GE Healthcare, Chicago, IL, USA) separation media. The PBMC obtained after centrifugation staining was used to determine cell viability by trypan blue before flow cytometry.

To separate tumor-infiltrating immune cells, newly resected tumor tissue (100 mg) and matching surrounding tissue from 22 Stage III or IV cervical cancer patients were cut into pieces and digested using 500 mg/ml Liberase (collagenase) and 200 mg/ml DNase (Roche Applied Science, Penzberg, Germany) for 45 min. The cell suspension was then passed through a 70-µm cell strainer (BD Biosciences). Centrifugation using a density gradient was then performed as described, and the corresponding cell layer was aspirated using a pipette.

In vitro inhibition analysis experiment

Fresh blood samples (20 ml) from three stage IV cervical cancer patients were used for PBMC extraction. CD11b-PECY7, HLA-DR-ECD, CD33-PECY5, Lineage-FITC, and CD3 monoclonal fluorescent antibodies were added to PBMCs before being sorted by the MoFloTM XDP cell sorting system (Beckman Coulter, Inc.). Sorted cells had a purity >95%. For MDSC functional analysis, purified CD3 T-cells were stained with 2 mM CFSE (Invitrogen; Thermo Fisher Scientific, Inc.) and CFSE-stained T-cells were cultured with Lin-/lowHLA-DR-CD11b+ CD33+ MDSCs at ratios of 1:0, 1:0.25, 1:0.5, and 1:1. Soluble anti-CD3 (2 mg/ml) and anti-CD28 (0.5 mg/ml) antibodies were added and cells were incubated for 24 h before being measuring proliferation through flow cytometry.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, United States); unpaired Student's t tests (Mann-Whitney test) and unparametric Spearman tests were used to assess differences and correlations between study groups, respectively. P<0.05 was considered to indicate a statistically significant difference.

Results <sec> <title>Increase in the proportion and numbers of peripheral Lin−/lowHLA-DR−CD11b+CD33+ MDSCs in cervical cancer patients

The proportion of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs in the peripheral blood of cervical cancer patients of different clinical stages was measured by flow cytometry (Table I shows clinical patients data). The ratio of MDSCs to total leukocytes in healthy volunteers, clinical stage I–II, and Stage III–IV patients was calculated using flow cytometry (as depicted in Fig. 1A). The proportion of MDSCs in cervical cancer patients was significantly higher compared to that in controls (P<0.0001; Fig. 1B). MDSC levels were also significantly increased in the peripheral blood of cervical cancer patients compared to that in controls (P<0.0001; Fig. 1C).

Further, the proportion of MDSCs in clinical stage III–IV patients was significantly higher than that in clinical stage I–II patients (P=0.0014; Fig. 1B). Next, we found that the absolute number of MDSCs in stage III–IV patients was significantly higher than that in stage I–II patients (P<0.0001; Fig. 1C).

Elevation in the proportion and numbers of tumor-infiltrating Lin−/lowHLA-DR−CD11b+CD33+ MDSCs in late stage cervical cancer patients

Fig. 2A depicts flow cytometry used to examine tumor-infiltrating MDSCs in cervical cancer patients. For all tumor-infiltrating CD45⁺ leukocytes, the proportion of MDSCs in cancer tissues was significantly increased compared to that in surrounding non-cancerous tissue (P<0.0001; Fig. 2B). The absolute count of MDSCs in cancer tissues was also significantly increased compared to that in surrounding non-cancerous tissue (P=0.001; Fig. 2C).

Functional characteristics of Lin−/lowHLA-DR−CD11b+CD33+ MDSCs

We used flow cytometry to analyze the phenotypic characteristics of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs, including myeloid and lymphoid markers (Fig. 3A). In the peripheral MDSCs of cervical cancer patients, CD13 was highly expressed, CD124 (IL-4Ra), CD115, and CD117 were lowly expressed, and CD66b, CD14, CD15, PDL1, PD1, CD34 were not expressed. These cells expressed high levels of CD39 but did not express CD73. Intracellular staining also failed to detect CD73 expression (results not shown); this was in accordance with a previous study on colorectal cancer (26). Similar to that observed in mouse MDSCs (14), PDL1 expression in Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs was low. No significant differences were observed with respect to these markers between normal and cervical cancer samples.

Previous studies showed that Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs can inhibit T-cell proliferation in other tumor types. We extracted highly pure (> 95%) MDSCs and CD3+ T-cells (Fig. 3B) from peripheral blood. CFSE-labeled CD3⁺ T cells were co-cultured with MDSCs at different ratios and stimulated with CD3 and CD28 antibodies. Upon analyzing CFSE fluorescence in CD4 and CD8 T cell subsets, we found that with an increasing proportion of MDSCs, CD4 and CD8 T cells were significantly inhibited (Fig. 3C and D).

MDSCs can function through multiple mechanisms, including inhibiting cytokine production in T cells. We tried to verify the effects of MDSCs from cervical cancer patients on CD4 and CD8 cells by analyzing IL-2 and IFN-γ in CD4 T-cells and IFN-γ production in CD8 T-cells. The cytokine production in CD4 and CD8 cells was decreased in the experimental MDSC group compared to that in the control group (no MDSCs) (Fig. 3E). IFN-γ production in CD8, and IFN-γ and IL-2 production in CD4 T cells, respectively, in the control and experimental groups (P=0.006, P=0.0024 and P=0.0372 respectively) (Fig. 3F). These data suggest that cervical cancer-associated MDSCs can inhibit cytokine production in T cells, resulting in decreased proliferation cytotoxicity.

Peripheral and tumor-infiltrating MDSCs is associated with metastasis in late stage cervical cancer

We further analyzed the proportions and absolute numbers of peripheral circulating MDSCs in late stage cervical cancer patients with tumor relapse and metastasis. Peripheral blood MDSCs from 22 patients were divided based on MDSC proportions into the high group (>mean value) and the low group (<mean value). Relapse was found to occur more readily in the high group (Fig. 4A). Although our results did not reach statistical significance (P=0.0531), some correlation was observed. Similarly, levels of peripheral MDSCs in clinical stage IV cervical cancer patients were found to significantly correlate with RFS (P=0.035; Fig. 4B).

We next analyzed the relationship between MDSC proportion and absolute counts and tumor recurrence and metastasis in 22 tumors from clinical stage IV cervical cancer patients. We observed that a higher proportion of MDSCs was significantly associated with recurrence (P=0.0466; Fig. 4C). MDSC levels in tumors were also found to be significantly associated with tumor recurrence and metastasis (P=0.0429; Fig. 4D). Thus, the proportion of peripheral and tumor-infiltrating MDSCs are related to tumor progression in cervical cancer patients.

Discussion

MDSCs play an important role in tumor immune evasion and tolerance. We examined changes in Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs in cervical cancer patients based on clinical stage and obtained results that were consistent with other tumor types.

The samples were all fresh, and conventional sample preparation protocols were used. In addition to examining MDSC phenotypes, we also assessed. In mice, MDSC populations have been verified (14), whereas in humans, three MDSC populations are recognized. A recent review introduced the phenotypes and characteristics of mouse and human MDSCs. Mouse MDSCs are classified as mixed MDSCs (Gr-1⁺CD11b⁺), which was further classified, based on Ly6C and Ly6 G expression, as PMN-MDSCs (CD11b⁺Ly6CloLy6G⁺) and M-MDSCs (CD11b⁺Ly6ChiLy6G⁻). There are three recognized human MDSC subsets, namely PMN-MDSCs (CD14⁻CD11b⁺CD15⁺/CD66b⁺), M-MDSCs (CD11b⁺CD14⁺HLA-DR^low/−CD15⁻), and E-MDSC (Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺). This review also summarized the biological functions of these MDSCs, including inhibiting T lymphocyte proliferation, IL-2 and IFN-γ production, and function (27). Our results were consistent with those previously reported; specifically, we found that MDSCs inhibit T-cell proliferation, IL-2 and IFN-γ production in CD4 T cells, and IFN-γ production in CD8 T cells.

In these other studies, changes in MDSCs were shown to correlate linearly with tumor burden (19,28,29). With increasing clinical stage, circulating MDSCs increase. Late stage cancer patients with higher levels of MDSCs are more prone to recurrence, which in turn affects prognosis (13). Similarly, we showed that peripheral circulating and tumor-infiltrating MDSC levels are associated with RFS. Possible reasons for these are as follows: Circulating tumor cells or tumor cells in the tumor microenvironment could secrete cytokines resulting in the expansion of MDSCs and produce pro-inflammatory and angiogenic cytokines to recruit MDSCs, promoting tumor proliferation and invasion (30).

Previous studies have shown that the proportion of MDSCs is higher in the microenvironment of different tumor types (21,31,32). We also showed that infiltrating MDSC numbers were increased in cervical cancer patients.

We found that Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs have a specific phenotypic profile. These cells highly express the myeloid marker CD13, exhibit low expression of CD115, CD124, and CD117, and do not express the monocytic marker CD14 or the granulocytic markers CD15 and CD66b. These phenotypes are generally similar to those previously reported (13). Interestingly, this population of cells highly expresses CD39 but not CD73, which both synergistically promote immunosuppression (33). These two molecules are expressed on human regulatory T cells and mediate an immunosuppressive effect (34), inhibiting the function of Th1, Th2, CTL, and NK cells (33,35). In a mouse study, the expression of CD39 and CD73 increased the immunosuppressive activity of MDSCs (36). We also found that this cell population expresses low levels of PD-L1 and does not express PD-L2 or its receptor PD-1 and B7 family members, but can still regulate the immune response and induce immune tolerance (37).

Consistent with the results of previous studies, circulating MDSCs were shown to inhibit T-cell proliferation. Some reports have confirmed that BM-MDSCs inhibit T-cell proliferation by decreasing their expression of CD3ε and CD3ξ (13). Our in vitro experiments also confirmed that Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs can inhibit IL-12 and IFN-γ production in T-cells and reduce T cell performance. BM-MDSCs also express arginase I, which depletes extracellular L-arginine, resulting in downregulation of CD3ε chain and diminished T-cell proliferation (17). Lastly, we confirmed that Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs are associated with tumor burden in cervical cancer. Abnormal accumulation of peripheral blood or local MDSCs is an important immunological mechanism of T cell anergy. Our studies could provide the foundation for immunotherapy to treat cervical cancer, and particularly immunotherapy targeting MDSCs.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LW performed flow cytometry and was a major contributor in writing the manuscript. HL and HG analyzed and interpreted the patient data for the cervical carcinoma patients, and were major contributors in writing the manuscript. QW and SY performed the separation of PBMC. YQ and LW performed the separation of tumor-infiltrating immune cells. GW and QW performed the in vitro inhibition analysis experiments. LZ and CL performed the collection of patient samples. RZ developed the methodology, performed data analysis and was a major contributor in revising the manuscript. TL and SJ made substantial contributions to the conception and design, analysis and interpretation of data, and fund support.

Ethics approval and consent to participate

The research protocol was approved by the Medical Ethics Committee of Chinese PLA General Hospital (Beijing, China) and the 307th Hospital of Chinese PLA (Beijing, China). All patients provided written informed consent for participation in the present study.

Consent for publication

Written informed consent was obtained from all participants.

Competing interests

The authors declare that they have no competing interests.

References 1

Bierman

Beardsley

Chang

Burk

Natural history of cervicovaginal papillomavirus infection in young women

N Engl J Med3384234281998

10.1056/NEJM199802123380703

9459645

Ferlay

Soerjomataram

Dikshit

Eser

Mathers

Rebelo

Parkin

Forman

Bray

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Int J Cancer136E359E3862015

10.1002/ijc.29210

25220842

Trottier

Franco

The epidemiology of genital human papillomavirus infection

Vaccine24Suppl 1S1S152006

10.1016/j.vaccine.2005.09.054

16406226

Woodman

Collins

Young

The natural history of cervical HPV infection: Unresolved issues

Nat Rev Cancer711222007

10.1038/nrc2050

17186016

Grabowska

Riemer

The invisible enemy-how human papillomaviruses avoid recognition and clearance by the host immune system

Open Virol J62492562012

10.2174/1874357901206010249

23341860

Kanodia

Fahey

Kast

Mechanisms used by human papillomaviruses to escape the host immune response

Curr Cancer Drug Targets779892007

10.2174/156800907780006869

17305480

Kobayashi

Weinberg

Darragh

Smith-McCune

Evolving immunosuppressive microenvironment during human cervical carcinogenesis

Mucosal Immunol14124202008

10.1038/mi.2008.33

19079205

Piersma

Immunosuppressive tumor microenvironment in cervical cancer patients

Cancer Microenviron43613752011

10.1007/s12307-011-0066-7

21626415

Jordanova

Gorter

Ayachi

Prins

Durrant

Kenter

van der Burg

Fleuren

Human leukocyte antigen class I, MHC class I chain-related molecule A and CD8+/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients?

Clin Cancer Res14202820352008

10.1158/1078-0432.CCR-07-4554

18381941

De Vos van Steenwijk

Ramwadhdoebe

Goedemans

Doorduijn

van Ham

Gorter

van Hall

Kuijjer

van Poelgeest

van der Burg

Jordanova

Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma

Int J Cancer133288428942013

23740735

Gabrilovich

Ostrand-Rosenberg

Bronte

Coordinated regulation of myeloid cells by tumours

Nat Rev Immunol122532682012

10.1038/nri3175

22437938

Gabrilovich

Nagaraj

Myeloid-derived suppressor cells as regulators of the immune system

Nat Rev Immunol91621742009

10.1038/nri2506

19197294

Solito

Falisi

Diaz-Montero

Doni

Pinton

Rosato

Francescato

Basso

Zanovello

Onicescu

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

Blood118225422652011

10.1182/blood-2010-12-325753

21734236

Youn

Nagaraj

Collazo

Gabrilovich

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

J Immunol181579158022008

10.4049/jimmunol.181.8.5791

18832739

Montero

Diaz-Montero

Kyriakopoulos

Bronte

Mandruzzato

Myeloid-derived suppressor cells in cancer patients: A clinical perspective

J Immunother351071152012

10.1097/CJI.0b013e318242169f

22306898

Greten

Manns

Korangy

Myeloid derived suppressor cells in human diseases

Int Immunopharmacol118028072011

10.1016/j.intimp.2011.01.003

21237299

Rodriguez

Ernstoff

Hernandez

Atkins

Zabaleta

Sierra

Ochoa

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

Cancer Res69155315602009

10.1158/0008-5472.CAN-08-1921

19201693

Almand

Clark

Nikitina

van Beynen

English

Knight

Carbone

Gabrilovich

Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer

J Immunol1666786892001

10.4049/jimmunol.166.1.678

11123353

Diaz-Montero

Salem

Nishimura

Garrett-Mayer

Cole

Montero

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden and doxorubicin-cyclophosphamide chemotherapy

Cancer Immunol Immunother5849592009

10.1007/s00262-008-0523-4

18446337

Srivastava

Bosch

Thompson

Ksander

Edelman

Ostrand-Rosenberg

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

Cancer Immunol Immunother57149315042008

10.1007/s00262-008-0490-9

18322683

Feng

Lee

Chang

Chan

Kuo

Lin

Chung

Kuo

Lin

CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer

Am J Respir Crit Care Med186102510362012

10.1164/rccm.201204-0636OC

22955317

Huang

Zhang

Wang

Zhang

Fan

Guo

Increased CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients

Cancer Immunol Immunother62143914512013

10.1007/s00262-013-1450-6

23760662

Kusmartsev

Heiser

Dannull

Eruslanov

Kübler

Yancey

Dahm

Vieweg

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

Clin Cancer Res14827082782008

10.1158/1078-0432.CCR-08-0165

19088044

Montero

Diaz-Montero

Deutsch

Hurley

Koniaris

Rumboldt

Yasir

Jorda

Garret-Mayer

Avisar

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

Breast Cancer Res Treat1322152232012

10.1007/s10549-011-1889-0

22138748

Raychaudhuri

Rayman

Ireland

Rini

Borden

Garcia

Vogelbaum

Finke

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

Neuro Oncol135915992011

10.1093/neuonc/nor042

21636707

Zhang

Wang

Zhang

Ding

Zhu

Wei

Zhao

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

PLoS One8e571142013

10.1371/journal.pone.0057114

23437326

Bronte

Brandau

Chen

Colombo

Frey

Greten

Mandruzzato

Murray

Ochoa

Ostrand-Rosenberg

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Nat Commun7121502016

10.1038/ncomms12150

27381735

Melani

Chiodoni

Forni

Colombo

Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity

Blood102213821452003

10.1182/blood-2003-01-0190

12750171

Bronte

Apolloni

Cabrelle

Ronca

Serafini

Zamboni

Restifo

Zanovello

Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells

Blood96383838462000

11090068

Ostrand-Rosenberg

Sinha

Myeloid-derived suppressor cells: Linking inflammation and cancer

J Immunol182449945062009

10.4049/jimmunol.0802740

19342621

Eruslanov

Neuberger

Daurkin

Perrin

Algood

Dahm

Rosser

Vieweg

Gilbert

Kusmartsev

Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer

Int J Cancer130110911192012

10.1002/ijc.26123

21480223

Corzo

Condamine

Cotter

Youn

Cheng

Cho

Celis

Quiceno

Padhya

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

J Exp Med207243924532010

10.1084/jem.20100587

20876310

Ghiringhelli

Bruchard

Chalmin

Rébé

Production of adenosine by ectonucleotidases: A key factor in tumor immunoescape

J Biomed Biotechnol20124737122012

10.1155/2012/473712

23133312

Deaglio

Dwyer

Gao

Friedman

Usheva

Erat

Chen

Enjyoji

Linden

Oukka

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

J Exp Med204125712652007

10.1084/jem.20062512

17502665

Bergamin

Braganhol

Zanin

Edelweiss

Battastini

Ectonucleotidases in tumor cells and tumor-associated immune cells: An overview

J Biomed Biotechnol20129598482012

10.1155/2012/959848

23118517

Ryzhov

Novitskiy

Goldstein

Biktasova

Blackburn

Biaggioni

Dikov

Feoktistov

Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells

J Immunol187612061292011

10.4049/jimmunol.1101225

22039302

Zou

Chen

Inhibitory B7-family molecules in the tumour microenvironment

Nat Rev Immunol84674772008

10.1038/nri2326

18500231

Figure 1.

Levels of peripheral blood Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs in normal subjects and cervical cancer patients. (A) Representative flow cytometry and analysis strategy. (B) Comparison of peripheral circulating MDSC proportions in normal controls (n=50) and cervical cancer patients (n=105; ***P<0.0001, as indicated), and comparison of patients in late stage with early stage (**P=0.0014, as indicated). (C) Comparison of absolute MDSC counts in normal controls (n=50) and cervical cancer patients (n=105; ***P<0.0001, as indicated), and comparison of patients in late stage with early stage (***P=0.0001, as indicated). MDSCs, myeloid-derived suppressor cells; HLA-DR, human leukocyte antigen-antigen D related; CD, cluster of differentiation; FSC, forward scatter; SSC, side scatter; HD, healthy donors.

Figure 2.

MDSCs increased in the tumor tissues of late stage cervical cancer patients. (A) Representative flow cytometry and analysis strategy. (B) Proportion and (C) absolute counts of MDSCs in tumor tissues and surrounding non-cancerous tissue. **P=0.001 and ***P<0.0001, as indicated. MDSCs, myeloid-derived suppressor cells; FSC, forward scatter; SSC, side scatter; CD, cluster of differentiation.

Figure 3.

Functional characteristics of Lin^−/lowHLA-DR⁻CD11b⁺CD33⁺ MDSCs. (A) Expression of indicated molecules (gray histograms represent isotype controls). (B) Flow cytometry was used to purify MDSCs and T cells. Representative flow cytometry prior to and following cell sorting. (C) Representative flow cytometry of the inhibitory effect of MDSCs on CD4 and CD8 T cells. (D) Quantitation of MDSC inhibition of CD8 and CD4 cells. *P<0.05, **P<0.01 and ***P<0.001, as indicated. (E) Representative flow cytometry of IL-12 and IFN-γ secretion by CD4 and CD8 cells. (F) The positive percentage of CD8 that secretes IFN-γ, and CD4 that secretes IFN-γ and IL-2, respectively (**P=0.006, **P=0.0024 and *P=0.0372, respectively). MDSCs, myeloid-derived suppressor cells; SSC, side scatter; CFSE, carboxyfluorescein succinimidyl ester; CD, cluster of differentiation; IL, interleukin; PD1, programmed cell death protein 1; PD-L, programmed cell death ligand; IFN, interferon.

Figure 4.

Peripheral blood and tumor-associated MDSCs in cervical cancer are associated with recurrence and progression. The levels of peripheral blood tumor tissue MDSCs from 22 late stage cervical cancer patients were assessed; the follow-up period was 24 months. (A) The associations between RFS and the proportion of peripheral MDSC. Patients were divided into two groups based on the mean value (6.4%), as the high (n=10) and low MDSC groups (n=12). (B) The associations between RFS and the absolute counts of peripheral MDSC. Patients were divided into two groups based on the mean value (300), as the high (n=10) and low MDSC groups (n=12). (C) The associations between RFS and the proportion of peripheral MDSC in tumors. Patients were divided into two groups based on the mean value (3.6%), as the high (n=11) and low MDSC groups (n=11). (D) The associations between RFS and the absolute counts of peripheral MDSC in tumors. Patients were divided into two groups based on the mean value (81), as the high (n=10) and low MDSC groups (n=12). MDSCs, myeloid-derived suppressor cells; RFS, relapse-free survival.

Table I.

Patient characteristics.

Variables	Total n number (%)
Number of patients (n)	105
Age [years; mean (SD)]	44.3 (7.8)
FIGO stage
Stage I	23 (21.9)
Stage II	28 (26.7)
Stage III	22 (21.0)
Stage IV	32 (30.4)
HPV type
16	76 (72.4)
18	24 (22.8)
Other	5 (4.8)
Histopathology
Squamous	64 (61.0)
Adeno (squamous)	41 (39.0)
Lymph node metastasis
Lymph nodes (+)	61 (58.1)
Lymph nodes (−)	44 (41.9)
Vasoinvasion
No	31 (29.5)
Yes	74 (70.5)
Parametrial involvement
No	26 (24.8)
Yes	79 (75.2)

SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomarvirus.